Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

REPONEX PHARMACEUTICALS A/S - Group

Quicksearch from your own companies XBRLDenmarkIFRS Analyst: XBRLDenmarkIFRS

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   4.5% 2.6% 2.9% 3.0% 2.9% 3.6% 6.9% 6.9%   Credit score (0-100)   48 63 58 56 58 51 35 35   Credit rating   BBB BBB BBB BBB BBB BBB BBB BBB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBITDA   -685 -1,947 -2,145 -12,604 -11,277 -16,600 0.0 0.0   EBIT   -1,337 -2,338 -2,302 -12,604 -11,277 -16,600 0.0 0.0   Pre-tax profit (PTP)   -1,596.3 -2,359.0 -2,382.8 -12,854.6 -11,299.0 -16,579.0 0.0 0.0   Net earnings   -1,256.7 -1,853.9 -1,504.9 -9,883.2 -9,444.0 -14,346.0 0.0 0.0   Pre-tax profit without non-rec. items   -1,596 -2,359 -2,383 -12,855 -11,299 -16,579 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 10.7 5.4 321 582 55.0 0.0 0.0   Shareholders equity total   2,397 14,933 13,428 27,371 18,911 16,757 0.0 0.0   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 13,598 13,598   Balance sheet total (assets)   9,694 17,502 20,409 28,708 21,516 21,662 13,598 13,598   Net Debt   -65.3 -2,538 -136 -11,403 -2,830 -1,938 13,598 13,598     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Gross profit growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   9,694 17,502 20,409 28,708 21,516 21,662 13,598 13,598   Balance sheet change%   22.8% 80.5% 16.6% 40.7% -25.1% 0.7% -37.2% 0.0%   Added value   -684.8 -1,947.3 -2,145.0 -12,603.8 -11,277.0 -16,600.0 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   1,341 4,094 4,530 -3,290 766 -789 -55 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -2.0 -3.0 -4.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -15.2% -17.2% -12.1% -51.3% -44.9% -76.6% 0.0% 0.0%   ROI %   -45.0% -30.3% -17.9% -63.9% -48.0% -90.1% 0.0% 0.0%   ROE %   -41.5% -21.4% -10.6% -48.4% -40.8% -80.4% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   24.7% 85.3% 71.0% 95.3% 87.9% 77.4% 0.0% 0.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   9.5% 130.3% 6.3% 90.5% 25.1% 11.7% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   3,460,626.7% 286,560.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.2 3.1 0.4 11.8 3.1 1.6 0.0 0.0   Current Ratio   0.3 3.8 0.6 12.8 3.1 1.6 0.0 0.0   Cash and cash equivalent   65.3 2,537.9 135.7 11,403.2 2,830.0 1,938.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -4,676.9 3,834.6 -2,049.4 13,857.7 4,764.0 2,886.0 -6,799.0 -6,799.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0